TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00450125

Intervention type: OTHER
Intervention: Six-Minute Walk Test
Description: Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests

Intervention type: OTHER
Intervention: Exercise stress test
Description: Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
Study: NCT02366091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
Study: NCT04636216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE parent training
Description: Weekly 1.5 hour parent training meetings for eight weeks
Study: NCT03595618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972
Description: Film-coated tablets of GLPG1972 for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972
Description: Film-coated tablets of GLPG1972 for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972
Description: Film-coated tablets of GLPG1972 for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablets of matching placebo for oral use.
Study: NCT04041856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone Ophthalmic
Description: Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
Study: NCT03607279

Intervention type: PROCEDURE
Intervention: NGAL

Intervention type: PROCEDURE
Intervention: NGAL
Study: NCT03595618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablets of matching placebo for oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablets of matching placebo for oral use.
Study: NCT02256397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard comprehensive care
Description: Standard comprehensive care at High Risk Children's Clinic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard comprehensive care
Description: Standard comprehensive care at High Risk Children's Clinic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced comprehensive care
Description: standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~* If between 2 and 5 years old--\> will receive Home-centered comprehensive care with the propeller~* 5 and above--\> will receive home-centered comprehensive care with propeller and PIKO
Study: NCT00042471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide acetate
Description: Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
Study: NCT04277806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Oral feeding process
Description: From the beginning of 32 weeks, try oral feeding once a day, suck pacifier for 10 minutes before feeding. When she/he can finish 50% of the amount of one meal in consecutive two days, and there is no adverse events happened, then we will try oral feeding twice a day. In the same way, in the oral feeding she/he can finish 50% of this meal in consecutive two days, there is no adverse events happened, then we will try three oral feedings three times a day. We wil continue the process until the infant can be fully oral fed by herself/himself.
Study: NCT03338322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twisted file adaptive
Description: Endodontic files that are used in preparation of root canals with adaptive motion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reciproc
Description: Endodontic files that are used in root canal preparation with reciprocation motion
Study: NCT03554343

Intervention type: DIAGNOSTIC_TEST
Intervention: test for SMN1 exon 7 deletion
Description: Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers
Study: NCT02895126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appui Parental program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular parental support
Study: NCT01105065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine 0.15%
Description: One drop in each eye three times a day for 8 weeks.
Study: NCT02711241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: 1 gram by slow IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Papaverine
Description: 80 mg by slow intravenous infusion
Study: NCT00883519

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy for Depressed Adolescents
Description: 12 psychotherapy sessions delivered over 16 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy for Depressed Adolescents
Description: 12 psychotherapy sessions delivered over 16 weeks
Study: NCT03988907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Part 1: a dose of 5 milligram (mg) risdiplam QD ; Part 2: precise dose will be based on Part 1 results

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Part 1: a dose of 5 milligram (mg) risdiplam QD ; Part 2: precise dose will be based on Part 1 results

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: single dose administration of 2 mg midazolam
Study: NCT02810964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane Nutraceutical
Description: Sulforaphane Nutraceutical 6 tablets by mouth daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical-appearing Placebo
Description: Identical-appearing Placebo 6 tablets by mouth daily
Study: NCT01052025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
Study: NCT00715988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone HCl Inject 10 mg/ml (will require dilution)
Description: Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 mg/ml (will require dilution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose
Study: NCT02273583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous oral cyclophosphamide and methotrexate
Study: NCT02277717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD985 (trastuzumab vc-seco-DUBA)
Description: IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.
Study: NCT01641939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Standard taxane (docetaxel 75 mg/m\^2 IV every 3 weeks or paclitaxel 80 mg/m\^2) IV once a week according to investigator choice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: trastuzumab emtansine 3.6 mg/kg IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: trastuzumab emtansine 2.4 mg/kg IV once a week
Study: NCT00883519

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy for Depressed Adolescents and Parents
Description: 12 psychotherapy sessions delivered over 16 weeks
Study: NCT04380064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ILM Peeling
Description: ILM peeling performed during primary PPV for PDR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ILM Peeling
Description: ILM peeling not performed during primary PPV for PDR
Study: NCT01410344

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine and Busulfan
Description: RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m\^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:~* Days -6 to -2: Flu (30 mg/m\^2/day, total dose of 150 mg/m\^2)~* Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m\^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m\^2 IV, respectively)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW.

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine and Melphalan
Description: RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m\^2, Melphalan total dose: less than or equal to 150 mg/m\^2. Recommended regimen:~* Days -5 to -2: Flu (30mg/m\^2/day, total dose of 120 mg/m\^2)~* Day -1: Mel (140mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan and Fludarabine
Description: MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m\^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:~* Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m\^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively)~* Days -5 to -2: Flu (30 mg/m\^2/day, total dose of 120 mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide and Total Body Irradiation
Description: MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~* Days -7 to -4: TBI (total dose of 1200-1420 cGy)~* Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight.
Study: NCT02122913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
Study: NCT00794898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab (Remicade)
Description: Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
Study: NCT04086498

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: The group received a plan for a isocaloric Mediterranean Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KEMEPHY
Description: The group received a plan for a ketogenic mediterranean with herbal extracts diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KD
Description: The group received a plan for a low carbohydrate ketogenic diet
Study: NCT05037578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Grace
Description: A multilevel church-based intervention to encourage cognitive screens and brain health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project Grace
Description: A multilevel church-based intervention to encourage cognitive screens and brain health.
Study: NCT02635932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Day Splint
Description: A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
Study: NCT03228160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linearly Polarized Near-Infrared light Irradiation
Description: The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Linearly Polarized Near-Infrared light Irradiation
Description: The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
Study: NCT02635932

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Night Splint
Description: A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
Study: NCT02782858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNbAC1
Description: Monthly IV repeated dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNbAC1
Description: Monthly IV repeated dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNbAC1
Description: Monthly IV repeated dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly IV repeated dose
Study: NCT02856152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0276 capsule
Description: Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0276 capsule
Description: Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0276 capsule
Description: Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0276 capsule
Description: Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.
Study: NCT04714515

Intervention type: DRUG
Intervention: Montelukast
Description: An FDA approved medicine to treat asthmatic patients

Intervention type: DRUG
Intervention: Montelukast
Description: An FDA approved medicine to treat asthmatic patients

Intervention type: DRUG
Intervention: Montelukast
Description: An FDA approved medicine to treat asthmatic patients

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: An FDA approved antiarthritis drug

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: An FDA approved antiarthritis drug

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: An FDA approved antiarthritis drug

Intervention type: DRUG
Intervention: Ivermectin
Description: An FDA approved anti-parasitic medicine
Study: NCT00883714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Instruction
Description: The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
Study: NCT02535182

Intervention type: OTHER
Intervention: Blood Draw
Description: Lab will draw one tube of blood to be stored in 8 mL Becton Dickinson (BD) Vacutainer Cell Preparation Tube (CPT) tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.~Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells.

Intervention type: OTHER
Intervention: Blood Draw
Description: Lab will draw one tube of blood to be stored in 8 mL Becton Dickinson (BD) Vacutainer Cell Preparation Tube (CPT) tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.~Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells.
Study: NCT04257994

Intervention type: DIAGNOSTIC_TEST
Intervention: obtaining a buccal smear sample
Description: A sample will be taken from the inside of the participants' cheeks using a soft brush
Study: NCT02167178

Intervention type: OTHER
Intervention: Administration of 0.9% NaCl solution
Description: Volunteers administered 0.9% NaCl solution in 250ml boluses

Intervention type: OTHER
Intervention: Measurement of stroke volume
Description: The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
Study: NCT02856152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0276 tablets
Description: Three 90 mg GDC-0276 tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0276 tablets
Description: Three 90 mg GDC-0276 tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0276 tablets
Description: Three 90 mg GDC-0276 tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0276 tablets
Description: Three 90 mg GDC-0276 tablets administered orally.
Study: NCT02167178

Intervention type: OTHER
Intervention: Measurement of stroke volume
Description: The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.

Intervention type: OTHER
Intervention: Measurement of microvascular blood flow
Description: Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.

Intervention type: OTHER
Intervention: Measurement of microvascular blood flow
Description: Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.

Intervention type: OTHER
Intervention: Administration of gelofusine
Description: Volunteers administered gelofusine in 250ml boluses